Mounjaro Butt: Why Tirzepatide Deflates the Buttocks, and How to Avoid and Fix It

“Mounjaro butt” is the social-media name for a deflated, flattened, or sagging backside after fast weight loss on Mounjaro (tirzepatide — the same molecule sold for weight management as Zepbound). It is not a toxic effect of tirzepatide on the buttocks. It is the cosmetic consequence of three things happening at once: the subcutaneous fat that gave the buttocks their roundness shrinks, a meaningful share of the weight lost is lean (muscle) mass — roughly a quarter of total weight loss in the SURMOUNT-1 DXA substudy (Look 2025^[1]) — so the gluteal muscles get smaller, and the previously stretched skin over a now-smaller area drapes and looks loose. What makes Mounjaro different is the sheer magnitude: tirzepatide drives the largest average weight loss of any GLP-1-class drug yet studied — about −20.9% body weight at the 15 mg dose in SURMOUNT-1 (Jastreboff 2022^[2]) — so the body-composition signal, and therefore “Mounjaro butt,” can be more pronounced than on lower-efficacy drugs. It belongs to the same family as “Mounjaro face.” The good news: the part you most control — the muscle — responds to the two interventions with the strongest evidence: resistance training and adequate protein.

What "Mounjaro butt" actually is

“Mounjaro butt” is a colloquial, not a medical, term. It describes a buttocks that looks smaller, flatter, softer, or saggier after substantial weight loss on tirzepatide (Mounjaro, or its weight-management twin Zepbound). People notice it as loss of projection and fullness, a “deflated” quality, crepey or loose skin over the upper thigh and lower glute, and sometimes a more pronounced fold where the buttock meets the thigh.

The crucial point is that this is not a drug toxicity aimed at the gluteal region. Tirzepatide has no known pharmacological action on buttock tissue specifically. It is the same phenomenon described for decades after bariatric surgery, very-low-calorie diets, and any other route to fast, large weight loss. Tirzepatide draws attention because it produces the biggest, fastest weight loss of the class — an average of about −20.9% body weight at 15 mg over 72 weeks in the SURMOUNT-1 pivotal trial (Jastreboff 2022^[2]), versus roughly −15% for semaglutide in STEP-1 (Wilding 2021^[3]). More total weight off, faster, means the body-composition change is simply more visible — which is why “Mounjaro butt” can look more dramatic than “Ozempic butt.”

Why it happens — fat loss, lean-mass loss, and skin laxity

1. Subcutaneous gluteal fat shrinks

The roundness and projection of the buttocks come largely from the gluteofemoral subcutaneous fat depot. This depot is metabolically distinct from belly fat — it is generally protective and slower to mobilize (Manolopoulos 2010^[4]) — but during a sustained, large caloric deficit it does shrink along with the rest of the body's fat stores. Because the buttock is a high-fat, low-other-tissue area, losing that subcutaneous fat has an outsized visual effect: there is less underneath to fill out the skin. On tirzepatide, where the total fat-mass loss is the largest of the class (SURMOUNT-1 DXA: fat mass fell about −33.9%, Look 2025^[1]), this is the single biggest driver of the deflated look — and to a large degree it is the intended result of the weight loss, the same fat loss that improves metabolic health.

2. A share of the weight lost is muscle

Every weight-loss method — diet, surgery, or GLP-1 — takes some lean (muscle) tissue along with the fat. In the SURMOUNT-1 DXA body-composition substudy (Look 2025^[1]), tirzepatide produced roughly −33.9% fat mass and −10.9% lean mass at week 72, so about 25% of the total weight lost was lean tissue — and the placebo arm showed the same fat-to-lean split, confirming the ratio reflects rate-of-weight-loss physiology, not a tirzepatide-specific effect. The catch with Mounjaro is arithmetic: because the total weight loss is so large, 25% of a bigger number is more absolute muscle lost than the same percentage of a smaller loss on a weaker drug. When the gluteus maximus and surrounding muscles lose volume, the buttocks lose their underlying shape and lift. Our GLP-1 muscle-loss prevention protocol covers the body-composition evidence in full.

3. Skin that was stretched now drapes

Skin that has been stretched over a larger volume for a long time does not always retract fully when the volume underneath disappears, especially with faster loss, larger total loss, older age, sun damage, and genetics. The result is laxity — crepey, loose, or sagging skin over the lower buttock and upper thigh. Because tirzepatide removes more total weight, the demand placed on skin retraction is correspondingly greater. See our guide on how to tighten loose skin after weight loss.

Put the three together — less fat, less muscle, looser skin — and you get the characteristic flattened, softened backside. The fat loss is mostly desired; the muscle loss and skin laxity are the parts worth actively managing — and managing them matters more, not less, on the most powerful drug in the class.

The body-composition evidence: how much of tirzepatide weight loss is lean mass

The honest, sourced numbers matter here, because the “muscle” part of “Mounjaro butt” is the part you can most influence.

• Tirzepatide (SURMOUNT-1 DXA substudy, Look 2025^[1]): at week 72, total body weight fell about −21.3% in the DXA cohort, fat mass −33.9%, lean mass −10.9% — so roughly 25% of total weight lost was lean tissue. The same 75/25 fat-to-lean split appeared in the placebo arm, confirming it is rate-of-loss physiology, not the drug.
• Magnitude is the Mounjaro story: tirzepatide 15 mg averaged about −20.9% total body weight in the full SURMOUNT-1 trial (Jastreboff 2022^[2]) — the largest mean weight loss of any GLP-1-class drug studied to date — versus about −14.9% for semaglutide in STEP-1 (Wilding 2021^[3]). A constant 25% lean fraction of a larger loss means more absolute muscle is at stake.
• Across all modalities (Cava 2017^[5]): the lean-tissue fraction of weight lost clusters around 20–30% for moderate-rate loss and tilts higher with faster loss — tirzepatide weight loss is not an outlier in its ratio, only in its scale.
• Rate matters: faster weight loss tends to take a higher proportion of lean tissue, which is why slower titration and protein-plus-training are the levers, especially on a high-efficacy drug (Stefanakis 2024^[9]).

The takeaway for the buttocks specifically: roughly a quarter of what you lose is, by default, lean mass — and on Mounjaro you are likely losing more total weight than on any other GLP-1, so the gluteal muscles, a large visible muscle group, are under more pressure. Protect that muscle and you protect a large part of the shape.

How to AVOID it — protect muscle while you lose fat

You cannot lose 15–25% of your body weight without some change to the buttocks — the fat that gave it volume is part of what is coming off. But you can substantially change how much of the loss is muscle versus fat, and you can preserve the underlying shape. Three interventions have the strongest evidence, and all three matter more on tirzepatide because the total loss is larger.

1. Resistance training, with glute-focused work, 2–3 sessions per week. This is the single highest-evidence intervention. Sardeli 2018^[6] meta-analyzed RCTs of resistance training during caloric restriction and found it essentially abolished the lean-mass loss otherwise seen with diet alone. Murphy and Koehler 2022^[10] showed that even in an energy deficit, resistance training still attenuates lean-mass loss and preserves strength. For the buttocks, prioritize compound lower-body movements that load the glutes — squats, hip hinges (deadlift, Romanian deadlift), and hip thrusts — alongside a full-body program.
2. Protein at 1.2–1.6 g/kg per day (up to ~2.0 g/kg on tirzepatide). Krieger 2006^[7] and Phillips 2016^[8] converge on roughly 1.6 g/kg as the practical target for preserving fat-free mass in a deficit; Longland 2016^[11] randomized men in a steep deficit to higher versus lower protein and the high-protein arm actually gained lean mass while losing fat; Wycherley 2012^[12] confirmed higher-protein diets reduce fat-free-mass loss. The challenge on Mounjaro is hitting the target when appetite is strongly suppressed — tirzepatide's appetite effect is potent, so prioritize protein first at each meal.
3. Slower titration / slower rate of loss, where appropriate. Because faster loss takes proportionally more lean tissue, and tirzepatide is titrated upward over months, discussing a more gradual dose escalation with your prescriber can reduce the share of weight lost as muscle and give skin more time to adapt (Stefanakis 2024^[9]).

How to FIX it — rebuild, tighten, and the cosmetic options

Rebuild the muscle (the highest-leverage fix)

The most effective and lowest-risk way to restore shape is to rebuild the gluteal muscle with progressive resistance training. Unlike fat loss, muscle can be regained, and the glutes respond strongly to direct loading. A program built around hip thrusts, squats, hip hinges, and lunges — 2–3 sessions per week with progressive overload — rebuilds the underlying volume and lift over weeks to months. Pairing this with adequate protein is what turns training into actual muscle. This is the same protocol used to prevent the change, applied after the fact; it works best once weight has stabilized so you are no longer in a steep deficit — relevant on Mounjaro, where the titration and weight-loss phase runs many months.

Skin tightening

Skin laxity is harder to reverse than muscle loss, and because tirzepatide removes more total weight, laxity can be more noticeable. Mild laxity often improves over months as skin slowly retracts, helped by reaching a stable weight, staying hydrated, not smoking, and protecting skin from sun. For more significant laxity, non-surgical energy-based devices (radiofrequency and ultrasound-based skin-tightening) are used cosmetically, and surgical options for the body exist for substantial excess skin — the post-bariatric body-contouring literature (Sadeghi 2022^[13]) describes these procedures, though most published work focuses on the abdomen and arms rather than the buttocks specifically. See our dedicated guide on tightening loose skin after weight loss.

Cosmetic volume restoration (elective)

If muscle rebuilding and skin tightening do not fully restore the desired shape, several elective cosmetic procedures can add volume. These are aesthetic, optional, and carry their own costs and risks — described here neutrally, not recommended:

• Autologous fat transfer (Brazilian butt lift, BBL): liposuctioned fat from elsewhere is injected into the buttocks to restore volume and projection. With the large weight loss tirzepatide produces, results depend on having enough donor fat left and on weight stability afterward — both can be limiting after a −20% loss.
• Biostimulatory injectables: agents such as poly-L-lactic acid and calcium hydroxylapatite are used off the face to stimulate collagen and add gradual volume to areas including the buttocks. These are non-surgical but require a series of sessions and have temporary results.
• Surgical gluteal augmentation / lift: for combined volume loss and significant skin excess — more likely after a large tirzepatide-driven loss — plastic surgeons offer buttock lift and augmentation procedures, sometimes alongside body-contouring after major weight loss.

For any of these, the practical advice mirrors the “Mounjaro face” guidance: time cosmetic intervention after weight has stabilized for a few months, because treating before the target weight is reached produces volume mismatches that need re-treatment as more weight comes off — a particular risk with tirzepatide's long, deep weight-loss trajectory. Bring your starting weight, current weight, and titration plan to the consultation.

Why muscle preservation matters beyond appearance

The gluteal and leg muscles are not only cosmetic — they are central to strength, balance, and metabolic health. Excess lean-mass loss matters most in older adults and in anyone at risk of sarcopenia (age-related muscle loss), and the larger the total weight loss, the more absolute lean tissue is at stake — which is exactly the Mounjaro scenario. The EWGSOP2 (Cruz-Jentoft 2019^[14]) and ESPEN/EASO sarcopenic-obesity (Donini 2022^[15]) consensus statements define when to screen muscle strength and mass formally — relevant for patients age 65 or older or with low baseline strength starting tirzepatide. The same resistance training and protein that keep the buttocks shapely also protect function and reduce fall and frailty risk. That is the strongest reason to treat the muscle side of “Mounjaro butt” seriously rather than purely cosmetically.

What about "Mounjaro butt and face" together?

People often notice changes to the buttocks and the face at the same time, and search for both together. Both are the same underlying phenomenon — rapid weight loss made visible in a high-fat, low-other-tissue area. The face and the buttocks both rely on subcutaneous fat for their fullness, so when fast weight loss strips that fat (plus some lean mass, plus skin that no longer retracts fully), both areas deflate. Neither is a drug effect targeting that body part; both track with how many kilograms are lost — and on tirzepatide that number is large, which is why both can be pronounced. The imaging evidence for the facial version, and the same prevention and treatment logic, is covered in our “Mounjaro face” article.

Bottom line

• “Mounjaro butt” is the deflated, flattened, or sagging buttocks seen after rapid tirzepatide weight loss — a body-composition and skin effect, not a drug toxicity to the buttocks.
• It is driven by three things: loss of gluteal subcutaneous fat, loss of gluteal muscle (about 25% of tirzepatide weight loss is lean mass per the SURMOUNT-1 DXA substudy^[1]), and skin laxity over a previously stretched area.
• It can look more pronounced than “Ozempic butt” because tirzepatide produces the largest average weight loss of the class — about −20.9% at 15 mg in SURMOUNT-1 (Jastreboff 2022^[2]) — so a constant lean fraction removes more absolute muscle.
• To avoid it: resistance training with glute-focused work 2–3x/week (Sardeli 2018^[6]), protein 1.2–1.6 g/kg (up to ~2.0 on tirzepatide), and slower titration where appropriate.
• To fix it: rebuild glute muscle with progressive resistance training (the highest-leverage, lowest-risk fix), support skin retraction, and — if desired — consider elective cosmetic options (fat transfer/BBL, biostimulators, surgical lift) once weight is stable.
• Preserving muscle protects strength, balance, and metabolic health, especially in older adults at risk of sarcopenia (Cruz-Jentoft 2019^[14]) — and matters more, not less, on the most powerful drug in the class.

Related research

• Ozempic butt — the same mechanism on semaglutide, with the lower-magnitude weight loss for comparison.
• Mounjaro face — the same subcutaneous-fat-loss mechanism in the face on tirzepatide.
• Preventing muscle loss on a GLP-1 — the resistance-training and protein protocol that protects the glutes.
• Tightening loose skin after weight loss — options for the skin-laxity component.

Important disclaimer. This article is educational and does not constitute medical, exercise, or cosmetic-procedure advice. Mounjaro (tirzepatide) is approved for type 2 diabetes; the same molecule is approved for weight management as Zepbound. Resistance-training programs should be individualized and, for patients with cardiovascular disease, prior injury, or significant deconditioning, supervised by a qualified clinician or certified strength coach. Protein targets assume normal renal function. Cosmetic and surgical procedures are elective and carry their own risks; discuss them with a board-certified provider. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-19.